Agennix AG Announces Data From Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase II Trial in Severe ...

3 September 2010, 1:15 am

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - September 3, 2010) - Agennix AG ( FRANKFURT : AGX ) ( XETRA : AGX ) announced that data from a Phase II trial with talactoferrin in severe sepsis were presented today at the Sepsis 2010 International Symposium, which was hosted by the International Sepsis Forum, in Paris, France. The double-blind, placebo ...... Read More »

More Topics from "News"

• Stony Brook-Millstone Watershed announces fundraiser event to be held at Eno Terra restaurant
• DiClemente will speak at substance abuse conference
• Trentonian Daily Police Blotter 9-4
• Americans Most Likely to Favor GOP Newcomers for Congress
• Blacks, Young Voters Not Poised for High Turnout on Nov. 2
• Toddler drowns in NJ backyard pool
• Thunder Announce Pitcher of the Year and Plumeri Community Service Award Winners
• Free Band of Changes with Joe Russo and Ween
• Charles C. Townsend Jr., Wall Street executive, Princeton civic leader